Ivosidenib

Chondrosarcoma

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 89/ 100

Competitive context

9 Active assets in the Chondrosarcoma cohort.

Asset / Sponsor	Phase	Rating
Angiotensin-(1-7) Wake Forest University Health Sciences	Phase 2	CCC
Azacitidine IGM Biosciences, Inc.	Phase 1/2	CCC
CIS-DIAMMINEDICHLOROPLATINUM II Eli Lilly and Company	Phase 1/2	CCC
Atezolizumab National Cancer Institute (NCI)	Phase 2	CCC
Adapt-001 EpicentRx, Inc.	Phase 2	CCC

View all 22 →

Same molecule, other indications

Ivosidenib is also rated in:

acute myeloid leukemia with multilineage dysplasiaActive

BB

Indicative · Phase 3

66 / 100

myeloproliferative neoplasmActive

B

Indicative · Phase 2

62 / 100

acute myeloid leukemiaActive

B

Indicative · Phase 3

61 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.